Amid GLP-1 boom, Novo Nordisk strikes up insulin partnership in Indonesia
Fierce Pharma
JULY 10, 2024
While much of the attention on Novo Nordisk these days revolves around the company’s wildly popular GLP-1 drugs Ozempic and Wegovy, insulin remains a critical backbone for the drugmaker. |
Let's personalize your content